These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12866482)

  • 1. Antiretroviral rounds. The when, why and how of switching.
    Henry K; Daar ES
    AIDS Clin Care; 2003 Jun; 15(6):58-9. PubMed ID: 12866482
    [No Abstract]   [Full Text] [Related]  

  • 2. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 3. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV treatment series. Treatment interruptions. Reviewing what we've learned so far.
    Staszow K
    Posit Aware; 2006; 17(3):37-40. PubMed ID: 16791962
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy 2002.
    Zambrano CH
    Posit Aware; 2002; 13(1):27. PubMed ID: 12216526
    [No Abstract]   [Full Text] [Related]  

  • 9. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to start antiretroviral therapy: a swinging pendulum?
    Gallant JE
    Top HIV Med; 2008; 16(2):82-8. PubMed ID: 18591715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.
    De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Guèye NF; Guèye PM; Sow PS; Mboup S; Ndoye I; Ecochard R; Eric D;
    Am J Trop Med Hyg; 2009 Jun; 80(6):1047-53. PubMed ID: 19478274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How infrequent are opportunistic diseases and immune reconstitution syndromes among HIV-infected individuals who have favorable CD4+ cell count responses to antiretroviral therapy?
    Phillips P
    Clin Infect Dis; 2005 May; 40(9):1379-80; author reply 1380-1. PubMed ID: 15825049
    [No Abstract]   [Full Text] [Related]  

  • 15. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies of HIV management--when to start.
    Youle M
    AIDS; 2002; 16 Suppl 4():S145-9. PubMed ID: 12699011
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral rounds. First holiday was a disaster: should she take another?
    Estanislao L; Simpson D; Cohen CJ
    AIDS Clin Care; 2004 May; 16(5):40-1. PubMed ID: 15199864
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV infection: in the HAART era, CD4 makes the difference].
    Varsky C
    Acta Gastroenterol Latinoam; 2004; 34(3):117-9. PubMed ID: 15742925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.